Skip to main content
. 2015 Sep 1;7(6):1195–1204. doi: 10.1080/19420862.2015.1086854

Figure 2.

Figure 2.

TTAC-0001 inhibits in vivo tumor growth in U-87MG xenograft models. (A) TTAC-0001 inhibits tumor growth in a U-87MG orthotopic xenograft model. Treatment groups exhibited significantly smaller tumor volumes (mean ± SE, n = 7) than control. (B) Paraffin embedded or frozen sections of the orthotopic tumors were stained for proliferating cells using anti-proliferating cell nuclear antigen (PCNA) antibody (upper panels), apoptotic cells using the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay (middle panels), and endothelial cells using anti-CD31 antibody (lower panels), respectively (scale bar = 200 µm). (C) PCNA-positive cells, TUNEL-positive cells, and microvessel density were quantified. (D) In the U-87MG orthotopic glioblastoma models, TTAC-0001 (1 mg/kg) treatment resulted in better tumor growth inhibition than bevacizumab, CPT-11, or bevacizumab + CPT-11 combination treatment. (E) Paraffin sections of U-87 MG tumors were stained with anti-CD31 antibody. Scale bar = 200 µm. * p< 0.05, ** p < 0.01, and *** p < 0.001 vs. Control. ## p < 0.001 vs. TTAC-0001 1 mg/kg.